Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL28479996 | 0.89 | CA12 (0.44) | CA12CA1CA2CA9TSHR | |
| SCHEMBL10892045 | 0.84 | ALDH1A1 (0.57) | TSHRTRPA1ALDH1A1CES2CES1 | |
| SCHEMBL3633054 | 0.82 | CA12 (0.61) | CA12CA1CA2CA9TSHR | |
| SCHEMBL29551674 | 0.82 | CA12 (0.61) | CA12CA1CA2CA9TSHR | |
| SCHEMBL8188945 | 0.81 | HDAC8 (0.50) | CA12CA1CA2CA9TSHR | |
| SCHEMBL9817061 | 0.81 | CA12 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9023806 | 0.80 | ALDH1A1 (0.59) | TSHRTRPA1ALDH1A1PPARGPPARA | |
| SCHEMBL4541662 | 0.79 | CA12 (0.59) | CA12CA1CA2CA9TSHR | |
| SCHEMBL29551646 | 0.79 | CA12 (0.59) | CA12CA1CA2CA9TSHR | |
| SCHEMBL11280987 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| US-8691999-B2 | Process for the preparation of telmisartan | CIPLA LIMITED (IN) | 2014-04-08 | — | — | US | disclosed |
| US-8445693-B2 | Catalyzed carbonylation in the synthesis of angiotensin II antagonists | LEK PHARMACEUTICALS D.D. (SI) | 2013-05-21 | — | — | US | disclosed |
| US-8410285-B2 | 2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists | LEK PHARMACEUTICALS D.D. (SI) | 2013-04-02 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110105539-A1 | 2'-HALOBIPHENYL-4-YL INTERMEDIATES IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS D.D. (SI) | 2011-05-05 | — | — | US | disclosed |
| US-20110098329-A1 | CATALYZED CARBONYLATION IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS D.D. (SI) | 2011-04-28 | — | — | US | disclosed |
| US-7884214-B2 | Condensing 4-Methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid with N-Methyl-O-phenylenediamine dihydrochloride to yields 4-methyl-6 (1-methyl benzimidazol-2-yl)-2-n-propyl 1H-benzimidazole, treating intermediate with 4'-(bromomethyl)-2-biphenyl-2-carboxylate in presence of a base, salt formation | MATRIX LABORATORIES LIMITED (IN) | 2011-02-08 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20090209603-A1 | Olmesartan medoxomil with reduced levels of impurities | HEDVATI LILACH | 2009-08-20 | — | — | US | disclosed |
| US-7563814-B2 | Olmesartan medoxomil with reduced levels of impurities | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| US-20090124814-A1 | Process for preparing telmisartan | PERLMAN NURIT | 2009-05-14 | — | — | US | disclosed |
| US-7501448-B2 | Process for preparing telmisartan | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-03-10 | — | — | US | disclosed |
| US-20090023932-A1 | Process for the Preparation of Telmisartan | MATRIX LABORATORIES LTD (IN) | 2009-01-22 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080015359-A1 | Process for the Preparation of Telmisartan | CIPLA LIMITED (IN) | 2008-01-17 | — | — | US | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-1991013063-A1 | NEW BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-09-05 | — | — | WO | disclosed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CA12 1613/4885CA1 1237/4885CA2 356/4885 |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | CA12 2801/4885CA1 2471/4885CA2 616/4885 |
| US-20110105539-A1 | 2'-HALOBIPHENYL-4-YL INTERMEDIATES IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS | ACE2, B2M, AGTR2 | CA12 1029/4885CA1 306/4885CA2 41/4885 |
| US-20090023932-A1 | Process for the Preparation of Telmisartan | ACE, ACE2, AGT | CA12 2033/4885CA1 3166/4885CA2 608/4885 |
| US-20090124814-A1 | Process for preparing telmisartan | AGT, ACE, REN | CA12 4377/4885CA1 4490/4885CA2 3413/4885 |
| US-20080015359-A1 | Process for the Preparation of Telmisartan | REN, ACE, AGT | CA12 2835/4885CA1 3807/4885CA2 772/4885 |
| US-20110098329-A1 | CATALYZED CARBONYLATION IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS | AGT, AGTR2, AGTR1 | CA12 223/4885CA1 78/4885CA2 17/4885 |
| US-20090209603-A1 | Olmesartan medoxomil with reduced levels of impurities | O60361, ADRB1, ADRM1 | CA12 4029/4885CA1 4769/4885CA2 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.